Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2013

01.12.2013 | short review

The contribution of antibodies to targeted cancer therapy

verfasst von: Panagiotis Apostolou, Dr. Ioannis Papasotiriou

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The fight against cancer is the focus of many research groups, as it is classified as one of the leading causes of death. The treatment of cancer is mainly composed of surgery, chemotherapy, radiation therapy, immunotherapy, and nowadays through targeted therapy as well. Targeted therapy targets the molecules whose expression correlates to carcinogenesis. It can be performed either with small molecule drugs or with monoclonal antibodies. Based on the capacity of the monoclonal antibodies to recognize a certain epitope of an antigen, and the fact that cancer cells express many antigens compared with normal (noncancer) cells abnormally in their surface, cytotoxicity may be induced directly in these cells. The cytotoxicity can be caused either via antibody-dependent cellular interaction or via the complement system. The possibility to create monoclonal antibodies against any antigen led to production of new medicines, many of which are already in clinical use. The ability to conjugate several molecules to antibodies also made the delivery of drugs/substances directly to cancer cells possible, thereby reducing the side effects of cancer treatment. This review presents the implementation of antibodies to targeted therapy, emphasizing the antibody-dependent cytotoxicity, as well as the monoclonal antibodies that are used in cancer treatment.
Literatur
1.
Zurück zum Zitat Joensuu H. Novel cancer therapies: more efficacy, less toxicity and improved organ preservation. Ann Med. 2000 Feb;32(1):31–3. Joensuu H. Novel cancer therapies: more efficacy, less toxicity and improved organ preservation. Ann Med. 2000 Feb;32(1):31–3.
2.
Zurück zum Zitat Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432(7015):294–7. Sawyers C. Targeted cancer therapy. Nature. 2004 Nov 18;432(7015):294–7.
3.
Zurück zum Zitat Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. 2009;2:2. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol. 2009;2:2.
4.
Zurück zum Zitat Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Investig Drugs. 2005 Jan;14(1):45–55. Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Investig Drugs. 2005 Jan;14(1):45–55.
5.
Zurück zum Zitat Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Apr;12(4):278–87. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Apr;12(4):278–87.
6.
Zurück zum Zitat Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657–62. Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. 1991 Jun 21;252(5013):1657–62.
7.
Zurück zum Zitat Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–6. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–6.
8.
Zurück zum Zitat Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005 Jan 31;92(2):342–9. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, Muller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005 Jan 31;92(2):342–9.
9.
Zurück zum Zitat Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease,. 5th edn. New York: Garland Science; 2001. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease,. 5th edn. New York: Garland Science; 2001.
10.
Zurück zum Zitat Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006 Apr;6(4):295–307. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006 Apr;6(4):295–307.
11.
Zurück zum Zitat Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003 Jun;8(3):237–49. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003 Jun;8(3):237–49.
12.
Zurück zum Zitat Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):73–80. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):73–80.
13.
Zurück zum Zitat Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J. 2013 Jan 8. doi: 10.1038/tpj.2012.54. (Epub ahead of print) Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J. 2013 Jan 8. doi: 10.1038/tpj.2012.54. (Epub ahead of print)
14.
Zurück zum Zitat Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39–51. Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39–51.
15.
Zurück zum Zitat Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res. 2013 Sep 15;19(18):4911–6. Blumenthal GM, Scher NS, Cortazar P, Chattopadhyay S, Tang S, Song P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res. 2013 Sep 15;19(18):4911–6.
16.
Zurück zum Zitat Thomas DA, O’Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):949–71, v. Thomas DA, O’Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009 Oct;23(5):949–71, v.
17.
Zurück zum Zitat Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393–402. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393–402.
18.
Zurück zum Zitat Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009;9:58. Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009;9:58.
19.
Zurück zum Zitat Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol. 2009 Sep;46(14):2794–800. Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol. 2009 Sep;46(14):2794–800.
20.
Zurück zum Zitat Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889–95. Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889–95.
21.
Zurück zum Zitat Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2005:329–34. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2005:329–34.
22.
Zurück zum Zitat Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003 Mar;9(3):269–77. Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003 Mar;9(3):269–77.
23.
Zurück zum Zitat Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013 Sep 13;341(6151):1192–8. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013 Sep 13;341(6151):1192–8.
24.
Zurück zum Zitat Zhang B. Ofatumumab. MAbs. 2009 Jul-Aug;1(4):326–31. Zhang B. Ofatumumab. MAbs. 2009 Jul-Aug;1(4):326–31.
25.
Zurück zum Zitat Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4875–82. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4875–82.
26.
Zurück zum Zitat Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328–35. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 Jul 29;333(2):328–35.
27.
Zurück zum Zitat Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010;3:15–25. Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010;3:15–25.
28.
Zurück zum Zitat Prieto PA, Yang JC, Sherry RM, Hughes MS,Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 1;18(7):2039–47. Prieto PA, Yang JC, Sherry RM, Hughes MS,Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 1;18(7):2039–47.
29.
Zurück zum Zitat Suarez N, Alfaro C, Dubrot J, Palazon A, Bolanos E, Erro L, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer. 2011 Jul 15;129(2):374–86. Suarez N, Alfaro C, Dubrot J, Palazon A, Bolanos E, Erro L, et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer. 2011 Jul 15;129(2):374–86.
30.
Zurück zum Zitat Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol. 2000 Aug;61(8):721–8. Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol. 2000 Aug;61(8):721–8.
31.
Zurück zum Zitat Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009 Nov-Dec;1(6):539–47. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009 Nov-Dec;1(6):539–47.
32.
Zurück zum Zitat Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010 Mar-Apr;2(2):129–36. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010 Mar-Apr;2(2):129–36.
33.
Zurück zum Zitat Pescovitz MD. Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor. Expert Rev Clin Immunol. 2005 Sep;1(3):337–44. Pescovitz MD. Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor. Expert Rev Clin Immunol. 2005 Sep;1(3):337–44.
34.
Zurück zum Zitat Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013 Mar 15;31(12):1553–9. Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013 Mar 15;31(12):1553–9.
35.
Zurück zum Zitat Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb;33(2):199–211. Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol. 2005 Feb;33(2):199–211.
36.
Zurück zum Zitat Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel. 2006 Oct;19(10):471–8. Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel. 2006 Oct;19(10):471–8.
37.
Zurück zum Zitat Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Sep;70(3):407–14. Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, et al. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Sep;70(3):407–14.
Metadaten
Titel
The contribution of antibodies to targeted cancer therapy
verfasst von
Panagiotis Apostolou
Dr. Ioannis Papasotiriou
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0117-5

Weitere Artikel der Ausgabe 4/2013

memo - Magazine of European Medical Oncology 4/2013 Zur Ausgabe